Jan Berger has a diverse work experience in the healthcare industry. Jan started their career in 2008 as the CEO of Health Intelligence Partners, where they currently hold the position. In 2009, they joined the American Journal of Pharmacy Benefit as the Editor in Chief, a role they held until 2017.
Throughout their career, they have served on various boards and as a board member in different organizations. Jan joined Tabula Rasa HealthCare in 2018 and UCB in 2019, both as a member of the Board of Directors. Jan also served as the Lead Independent Board of Director at GNS Healthcare since 2013, and as a Board Member at Cambia Health Solutions from 2016 to 2022.
In addition, they have also been involved in non-profit organizations and served as a Board Member at AccentCare, Inc. from 2013 to 2019, at Savor Health from 2012 to 2018, and at Voluntis from 2018 to 2021.
Jan Berger's extensive experience and involvement in various healthcare organizations indicate their expertise in the industry and their commitment to advancing healthcare initiatives.
Jan Berger attended Loyola University Chicago Stritch School of Medicine from 1979 to 1982 and earned a Doctor of Medicine (MD) degree. From 1987 to 1989, they attended Loyola University Chicago School of Law and obtained a Master of Jurisprudence degree. Jan also received a Certificate of Business Administration from the University of South Florida, although the specific start and end years for this program were not provided.
Org chart
Teams
This person is not in any teams
Offices
This person is not in any offices
Aitia
1 followers
Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.
